Name: Danazol
SKU: 17230-88-5

Products Categories

Pharmaceutical (92)
Organic Chemicals (17)
Others (4)
Basic Inorganic Chemicals (2)
Reagent (1)
Materials (1)
(1)

Basic Information

Molecular Structure:
CAS No.:	17230-88-5
Name:	Danazol
Article Data:	5

Formula:	C₂₂H₂₇NO₂
Molecular Weight:	337.462
Synonyms:	17a-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol(8CI);1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol, 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-(7CI);Bonzol;Cyclomen;Danalem;Danazolum;Danocrine;Danol;Ladogal;NSC 270916;Win 17757;Winobanin;
EINECS:	241-270-1
Density:	1.21 g/cm³
Melting Point:	224.4-226.8 °C
Boiling Point:	478.2 °C at 760 mmHg
Flash Point:	243 °C
Solubility:	Partly soluble in water. Soluble in chloroform (25 mg/ml), acetone, acetonitrile, and ethanol. 17beta-Hydroxy-2,4,17a-pregnadien-20-yno[2,3-d]isoxazole and 2,4,17a-Pregnadien-20-yno[2,3-d]isoxazol-17-ol are the synonym of this compound.
Appearance:	White solid
Hazard Symbols:	Xn,Xi
Risk Codes:	20/21/22-63-36/37/38
Safety:	22-36-37/39-26
PSA:	46.26000
LogP:	4.22100

Country:
Business Type:
All

Lab/Research institutions

Trading Company

Manufacturers

Other
Certificate:
Manufacturer

Enterprise Authentication

ISO

GMP

FDA

HALAL

Display:default sort
Suppiers of more reward points first

New supplier

Total:103 Page 1 of 3 1 2 3 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 17230-88-5

Specification

The Danazol, with the CAS registry number 17230-88-5, is also known as 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol. It belongs to the product categories of Steroids; Organics; Intermediates & Fine Chemicals; Pharmaceuticals. Its EINECS registry number is 241-270-1. This chemical's molecular formula is C₂₂H₂₇NO₂ and molecular weight is 337.5. Its systematic name is called (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.^02,10.0^4,8.0^14,18]icosa-4(8),5,9-trien-17-ol. This chemical's classification codes are Anterior pituitary suppressant; Drug / Therapeutic Agent; Estrogen Receptor Modulators; Estrogen antagonists; Hormone; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Human Data; Mutation data; Reproductive Effect; Tumor data.

Physical properties of Danazol: (1)ACD/LogP: 4.70; (2)ACD/LogD (pH 5.5): 4.7; (3)ACD/LogD (pH 7.4): 4.7; (4)ACD/BCF (pH 5.5): 2202.59; (5)ACD/BCF (pH 7.4): 2202.59; (6)ACD/KOC (pH 5.5): 8599.41; (7)ACD/KOC (pH 7.4): 8599.39; (8)#H bond acceptors: 3; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 1; (11)Index of Refraction: 1.603; (12)Molar Refractivity: 95.82 cm³; (13)Molar Volume: 278.6 cm³; (14)Surface Tension: 55 dyne/cm; (15)Density: 1.21 g/cm³; (16)Flash Point: 243 °C; (17)Enthalpy of Vaporization: 78.19 kJ/mol; (18)Boiling Point: 478.2 °C at 760 mmHg; (19)Vapour Pressure: 5.94E-10 mmHg at 25°C.

Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. Although effective for endometriosis, its use is limited by its masculinizing side-effects. Its role as a treatment for endometriosis has been largely replaced by the GnRH agonists. The agent is fat-soluble. It is an isoxazole of testosterone with isolated weak androgenic activity and no estrogenic or progestagenic effects. Danazol is contraindicated in pregnancy because it could masculinize a female fetus.

When you are using this chemical, please be cautious about it as the following:
This chemical may cause inflammation to the skin or other mucous membranes and may cause damage to health. It is harmful by inhalation, in contact with skin and if swallowed. In addition, it is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. Whenever you will contact it, please wear suitable protective clothing, gloves and eye/face protection.

You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
(2)Isomeric SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
(3)InChI: InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
(4)InChIKey: POZRVZJJTULAOH-LHZXLZLDSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	> 5gm/kg (5000mg/kg)		Journal of International Medical Research. Vol. 5(Suppl,
man	TDLo	oral	274mg/kg/32D- (274mg/kg)	LIVER: "JAUNDICE, CHOLESTATIC" LIVER: OTHER CHANGES SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Postgraduate Medical Journal. Vol. 69, Pg. 237, 1993.
man	TDLo	oral	1029mg/kg/17W (1029mg/kg)	LIVER: "JAUNDICE, CHOLESTATIC"	Postgraduate Medical Journal. Vol. 68, Pg. 984, 1992.
mouse	LD50	intraperitoneal	6770mg/kg (6770mg/kg)		Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983.
mouse	LD50	oral	4830mg/kg (4830mg/kg)		Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 25, Pg. 55, 1990.
mouse	LD50	subcutaneous	> 10gm/kg (10000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983.
rabbit	LD50	oral	> 5gm/kg (5000mg/kg)		Journal of International Medical Research. Vol. 5(Suppl,
rat	LD50	intraperitoneal	> 10gm/kg (10000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983.
rat	LD50	oral	> 17gm/kg (17000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983.
rat	LD50	subcutaneous	> 10gm/kg (10000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983.
women	TDLo	oral	120mg/kg/10D- (120mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE"	Archives of Internal Medicine. Vol. 145, Pg. 2251, 1985.
women	TDLo	oral	974mg/kg/23W- (974mg/kg)	PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE SENSE ORGANS AND SPECIAL SENSES: DIPLOPIA: EYE BEHAVIORAL: HEADACHE	Therapie. Vol. 43, Pg. 501, 1988.